Carl C Atkinson

US Patent:

20120171206, Jul 5, 2012

Filed:

Jul 2, 2010

Appl. No.:

13/380477

Inventors:

Stephen Tomlinson - Mount Pleasant SC, US
Songqing He - Charleston SC, US
Carl Atkinson - Mount Pleasant SC, US

International Classification:

A61K 39/395
A61P 1/16
A61K 38/17

US Classification:

4241341, 514 209

Abstract:

Provided herein are methods and compositions, including pharmaceutical compositions, for stimulating liver regeneration after partial hepatectomy, massive liver resection and toxic injury, or following liver transplantation, including small-for-size liver transplantation, by inhibiting activation of complement.

US Patent:

20210388080, Dec 16, 2021

Filed:

Apr 12, 2021

Appl. No.:

17/228279

Inventors:

- Denver CO, US
- Charleston SC, US
- Washington DC, US
Joshua M. Thurman - Greenwood Village CO, US
Carl Atkinson - Mount Pleasant SC, US
Liudmila Kulik - Aurora CO, US

International Classification:

C07K 16/28
A61K 39/395
A61K 45/06

Abstract:

The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognizes an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereor or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.

US Patent:

20200281190, Sep 10, 2020

Filed:

Dec 26, 2018

Appl. No.:

16/339179

Inventors:

- Charleston SC, US
Carl Atkinson - Mt. Pleasant SC, US
Danh T. Tran - Charleston SC, US

International Classification:

A01N 1/02
C07C 251/86
C07D 239/95

Abstract:

Provided herein is a formulation to pre-treat an organ prior to transplantation and for inducing mitochondrial morphological alterations.

US Patent:

20200056183, Feb 20, 2020

Filed:

Aug 23, 2019

Appl. No.:

16/548945

Inventors:

- Charleston SC, US
Suraj Dixit - Charleston SC, US
Satish Nadig - Johns Island SC, US
Carl Atkinson - Mt. Pleasant SC, US

International Classification:

C12N 15/117
A61K 38/17
A61K 38/13
A61K 35/17
A61K 31/713
A61K 31/436
A61K 31/365
C12N 15/11
A61K 38/20
A61K 31/395
A61K 47/69
A61K 47/62

Abstract:

Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

US Patent:

20190247511, Aug 15, 2019

Filed:

Oct 17, 2017

Appl. No.:

16/342868

Inventors:

- Charleston SC, US
Carl ATKINSON - Charleston SC, US
Xue-Zhong YU - Charleston SC, US

International Classification:

A61K 47/68
A61K 38/00
C07K 16/18
A61K 35/28
A61K 38/13
A61K 31/436
A61K 31/675
A61K 31/573
A61P 37/06

Abstract:

Described herein are compositions and methods for treating or preventing an injury associated with transplant. Specifically, the disclosure provides a composition for treating or preventing an injury associated with transplantation, comprising (a) a targeted inhibitor molecule wherein the targeted inhibitor molecule comprises a targeting portion and an inhibitor portion, wherein the molecule inhibits complement pathways, and (b) a sub-therapeutic dose of an immunosuppressant agent. Further provided are methods of treating or preventing an injury associated with transplantation with activated complement by using the compositions.

US Patent:

20180338963, Nov 29, 2018

Filed:

Jun 24, 2016

Appl. No.:

15/745913

Inventors:

- Charleston SC, US
Carl ATKINSON - Mt. Pleasant SC, US
Ann-Marie BROOME - Mt. Pleasant SC, US
Suraj K. DIXIT - Charleston SC, US

International Classification:

A61K 31/453
A61K 31/343
A61K 38/13
A61K 47/10
A61K 47/18
A61K 9/107
A61K 9/127
A61K 9/51
A61K 38/20
A61P 37/06

Abstract:

Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.

US Patent:

20160317670, Nov 3, 2016

Filed:

Jan 14, 2015

Appl. No.:

15/107536

Inventors:

- Charleston SC, US
Suraj Dixit - Charleston SC, US
Satish Nadig - Johns Island SC, US
Carl Atkinson - Mt. Pleasant SC, US

International Classification:

A61K 47/48
A61K 38/13
A61K 31/713
A61K 31/365
A61K 35/17
C12N 15/117
A61K 31/436
A61K 38/17

Abstract:

Disclosed is a nanocarrier-containing immunosuppressive agent that is targeted to C3 breakdown products, integrin, or a combination thereof, to reduce the deleterious systemic effects of the immunosuppressive agent. Also disclosed is a method for suppressing an allo-immune response in a subject, such as one that can occur after an allograft transplantation.

US Patent:

20160083469, Mar 24, 2016

Filed:

Jul 23, 2015

Appl. No.:

14/807521

Inventors:

- Denver CO, US
- Charleston SC, US
- Washington DC, US
Joshua M. Thurman - Greenwood Village CO, US
Carl Atkinson - Mount Pleasant SC, US
Liudmila Kulik - Aurora CO, US

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395

Abstract:

The present invention provides targeted delivery methods and constructs for treating inflammatory diseases and/or detecting in vivo tissue injuries in an individual. The targeted delivery approach utilizes an antibody that recognises an epitope found to be present at sites of inflammation. The invention also provides methods of inhibiting complement-driven inflammation in the eye in an individual, comprising administering to the individual an antibody or a fragment thereof or compositions thereof, wherein the antibody or fragment thereof specifically binds to Annexin IV or phospholipid. Also provided are related methods of treating a complement-associated ocular disease or an ocular disease involving oxidative damage. Additionally, the invention provides methods of detecting complement-mediated injury in an eye tissue of an individual, comprising administering to the individual a construct or compositions thereof, wherein the construct comprises (a) an antibody or fragment thereof that specifically binds to Annexin IV or phospholipid; and (b) a detectable moiety.